scholarly journals Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

2018 ◽  
Vol 36 (2) ◽  
pp. 138-147 ◽  
Author(s):  
Vanita R. Aroda ◽  
Joseph R. Arulandu ◽  
Anthony J. Cannon
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Receptor Agonist ◽  
Two Agents ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Better Than

Efficacy of dapagliflozin in combination therapy with the glucagon-like peptide-1 analog in obese patients with type 2 diabetes

2015 ◽  
Vol 2 (e1) ◽  
pp. 008-008
Author(s):  
Momoko Isono ◽  
Kazuya Fujihara ◽  
Shoko Furukawa ◽  
Ryo Kumagai ◽  
Hiroaki Yagyu
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Obese Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document